| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 340.98% | £308,687.71 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 315.10% | £290,569.22 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 218.78% | £223,148.92 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 45.23% | £101,661.59 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 34.79% | £94,355.05 |
| Lord Mance |
|
Stryker / NYQ:SYK | 11.32% | £77,924.00 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Baroness Deech |
|
Smith & Nephew / NYQ:SNN | 2.11% | £71,477.88 |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | -0.84% | £69,411.68 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | -3.62% | £67,465.54 |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -5.93% | £65,845.99 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -44.38% | £38,934.06 |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** | |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | -99.70% | £211.48 |